Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProShares Trust Ultra VIX Short Term Futures ETF UVXY



ARCA:UVXY - Post by User

Post by thegreenmile656on Dec 12, 2022 8:34am
61 Views
Post# 35165666

Futures Trade Near Session Highs After Last Week's Rout

Futures Trade Near Session Highs After Last Week's Rout https://www.zerohedge.com/markets/futures-trade-near-session-highs-after-last-weeks-rout-cpi-fomc-loom

Futures Trade Near Session Highs After Last Week's Rout With CPI, FOMC On Deck

by Tyler Durden

Monday, Dec 12, 2022 - 07:55 AM

After tumbling on Friday and slumping for 9 of the past 11 days, US stock futures staged a modest rebound after opening lower ahead of a crunch week for markets, which also is the last real week of 2022, with investors bracing for the release of US inflation data tomorrow and the Federal Reserve’s 50bps rate hike on Wednesday. Contracts on the S&P 500 and the Nasdaq 100 were up 0.2% and 0.3%, respectively, as of 7:30 a.m. ET; the underlying indexes both ended down last week, snapping a two-week winning streak. The S&P 500 had its biggest weekly decline since September last week; the Nasdaq 100 has already receded 3.9% this month, while the S&P 500 is down 3.6%.



In premarket trading, Rivian Automotive fell after the electric vehicle maker said it would walk away from plans to jointly build vans in Europe with Mercedes-Benz. Amgen slipped after reports the biopharmaceutical company had agreed to purchase Horizon Therapeutics at a valuation of $26 billion. Coupa Software jumped on a report that Thoma Bravo was in advanced talks to acquire the company.
<< Previous
Bullboard Posts
Next >>